The RAD101 Phase 3 start in 1Q27 is the primary near-term catalyst. Cash runway appears sufficient for about 2 quarters at current burn rate, making additional financing likely before the Phase 3 trial completes. Monitor enrollment updates and any partnership announcements.
Price Chart
How similar events traded
Executive Summary
Radiopharm Theranostics reported a net cash position of $7.5M at quarter-end, up from $4.1M, and completed a A$12.5M institutional placement plus a A$3M SPP. The key catalyst is the successful End-of-Phase 2 meeting with the FDA for RAD101, enabling a Phase 3 registrational trial in brain metastases, with positive Phase 2b data showing 93% concordance with MRI. The company also reported positive Phase 1 imaging data for RAD301 in pancreatic cancer and advanced RAD202 to a fourth dosing cohort.
Key Financial Metrics
Key Facts
- End-of-Phase 2 meeting with FDA for RAD101 completed; Phase 3 registrational trial expected to initiate in 1Q27
- Phase 2b data for RAD101 showed 93% concordance with MRI across all evaluable lesions, meeting primary endpoint
- Positive Phase 1 imaging data for RAD301 in pancreatic ductal adenocarcinoma reported
- RAD202 advanced to fourth dosing cohort (180mCi) in Phase 1 HEAT study
- First patient dosed in second cohort of RV-01 Phase 1/2 trial
- Closing cash $7.5M (up from $4.1M prior quarter)
- Completed A$12.5M institutional placement and A$3M Share Purchase Plan
- Received A$5.9M R&D tax refund for FY2025
- Received $8M from Rockford Capital against anticipated FY26 R&D tax incentive
- Net cash outflows from operations were $10.7M for the quarter
Financial Impact
Cash position $7.5M; raised A$15.5M in equity; received A$5.9M R&D refund and $8M advance; net operating cash burn $10.7M/quarter
Risk Factors
- Cash burn rate of $10.7M/quarter implies limited runway beyond ~2 quarters at current cash of $7.5M plus $8M advance
- All pipeline candidates are in early-stage (Phase 1/2) with no approved products or revenue
- Dilution from recent equity raises (A$15.5M) and potential future financing needs
- Clinical trial risks: failure to meet endpoints in Phase 3 RAD101 or other ongoing studies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393068 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | 6-K | $0.9139 | awaiting T+5 | awaiting T+5 | $0.8900 (−2.62%) |
Nov 4, 2026 today | Press Release | $0.9450 | awaiting T+5 | awaiting T+5 | $0.8900 (−5.82%) |
Nov 2, 2026 2d ago | Press Release | $0.9931 | awaiting T+5 | awaiting T+5 | $0.8900 (−10.38%) |
Oct 30, 2026 5d ago | 6-K | $1.08 | awaiting T+5 | awaiting T+5 | $0.8900 (+17.59%) |
Oct 27, 2026 8d ago | 6-K | $0.9000 $0.8901 | ▼ −1.10% | ▲ +0.89% | $0.8900 (−1.11%) |
Oct 26, 2026 9d ago | 6-K | $0.9960 $1.08 | ▲ +8.43% | ▲ +9.69% | $0.8900 (−10.64%) |
Oct 20, 2026 15d ago | 6-K | $0.9900 $0.9000 | ▼ −9.09% | ▼ −9.17% | $0.8900 (−10.10%) |
Oct 14, 2026 20d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.8900 (−17.59%) |
Oct 5, 2026 4w ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.8900 (−29.92%) |
Oct 1, 2026 4w ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.8900 (−39.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers